Sanofi Consumer Healthcare India Ltd

Sanofi Consumer Healthcare India Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the Financial Year ended December 31, 2025. The report, which is part of the Annual Report, details the company's operations, employee data, and market presence. Key disclosures include 100% turnover from Drugs and Pharmaceuticals, operations serving 29 national and 4 international markets, and a workforce of 518 employees and 79 workers. The company also reported a 19% contribution from exports to its total turnover.

Sanofi Consumer Healthcare India Ltd has filed its Annual Report for the Financial Year 2025. The report includes the Notice of the 3rd Annual General Meeting (AGM) scheduled for June 26, 2026, to be held via Video Conferencing. Key dates for e-voting, remote e-voting, and book closure have been announced. The dividend payment date is set for July 9, 2026. The Annual Report details the company's performance highlights, business strengths, strategy, portfolio, CSR initiatives, and corporate governance for the fiscal year ended December 31, 2025.

Sanofi Consumer Healthcare India Ltd has announced its 3rd Annual General Meeting (AGM) scheduled for Friday, June 26, 2026, at 3:00 PM IST, to be conducted via Video Conferencing. Key agenda items include the adoption of the Annual Audited Standalone Financial Statements for the year ended December 31, 2025, the declaration of a final dividend of ₹75 per equity share, the re-appointment of Mr. Stanislas Camart as Director, and the appointment of M/s. Price Waterhouse & Co Chartered Accountants LLP as Statutory Auditors for a term of five years. The meeting will also address the filling of a casual vacancy for Statutory Auditors.

Sanofi Consumer Healthcare India Ltd will hold its 3rd Annual General Meeting on June 26, 2026, via VC/OAVM. The Register of Members and Share Transfer Books will be closed from June 20, 2026, to June 26, 2026, for the purpose of determining eligibility for the final dividend. The record date is set for June 19, 2026. The Annual Report for FY2025 and AGM notice will be dispatched to shareholders.

Sanofi Consumer Healthcare India Ltd has announced that the record date for the payment of the final dividend for the financial year 2025 is Friday, June 19, 2026. The 3rd Annual General Meeting (AGM) of the company will be held on Friday, June 26, 2026, via video conferencing. The Register of Members and Share Transfer Books will be closed from June 20, 2026, to June 26, 2026, both days inclusive.

Sanofi Consumer Healthcare India Ltd has appointed M/s. Price Waterhouse & Co Chartered Accountants LLP as the Statutory Auditors of the Company to fill the casual vacancy caused by the resignation of M/s. Kalyaniwalla & Mistry LLP. The appointment is effective from May 25, 2026, until the conclusion of the ensuing AGM, subject to shareholder approval. Furthermore, the Board approved their appointment for a 5-year term, commencing from the conclusion of the 2026 AGM until the conclusion of the 2031 AGM, also subject to shareholder approval.

Sanofi Consumer Healthcare India Ltd appointed M/s. Price Waterhouse & Co Chartered Accountants LLP as the Statutory Auditors, effective May 25, 2026, to fill the vacancy caused by the resignation of M/s. Kalyaniwalla & Mistry LLP. The appointment is subject to shareholder approval at the upcoming AGM. Price Waterhouse & Co will serve until the AGM's conclusion and is also approved for a 5-year term from the 2026 AGM until the 2031 AGM, pending shareholder approval.

Nippon India Mutual Fund acquired additional shares of Sanofi Consumer Healthcare India Ltd, increasing its stake to 5.0458%. The acquisition involved purchasing 30,000 shares through open market transactions between June 14, 2024, and April 29, 2026. This disclosure is under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sanofi Consumer Healthcare India Limited (SCHIL) announced its unaudited financial results for the first quarter ended March 31, 2026. The company reported a 33% year-on-year growth in revenue, reaching ₹2,292 million. Domestic sales increased by 15.5%, primarily driven by the successful relaunch of recalled products. Export sales saw a substantial 144% growth, albeit from a low base. Profit After Tax (PAT) for Q1'26 stood at ₹678 million, marking a 36% increase compared to the previous year. Managing Director Himanshu Bakshi emphasized consistent, disciplined execution, with the domestic business outpacing the market and exports making a meaningful contribution.

Sanofi Consumer Healthcare India Ltd's Board of Directors, at its meeting on April 28, 2026, approved the unaudited financial results for the quarter ended March 31, 2026. The company enclosed a copy of these results along with a Limited Review Report from its Statutory Auditors, Kalyaniwalla & Mistry LLP, as per SEBI Listing Regulations. The auditors confirmed that their review, conducted under SREs 2410, found no material misstatement in the financial statements, which were prepared in accordance with Ind AS 34. The results will be published in newspapers and made available on the company's website. The board meeting started at 1:00 p.m. and concluded at 3:40 p.m.